Drug
CS-1003 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 1
- first study started
- 2018
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
CS1002 (1) · Ipilimumab (1)
Studies
Open first, then newest update. How each study uses CS-1003 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingPhase 3CStone PharmaceuticalsNCT04194775Written as Nofazinlimab (CS1003)+Lenvatinib
- A Study of CS1002 in Subjects with Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT03523819Written as CS1003
- A Study of CS1003 in Subjects With Advanced Solid Tumors or LymphomasCompletedPhase 1CStone PharmaceuticalsNCT03809767Written as CS1003 monoclonal antibody
Given in every arm · 1 — CS-1003 is usual care beside what is tested
Codes
What other systems call CS-1003 · ClinicalTrials.gg INT001705
- MeSH (NLM) C000719047CS-1003Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 42T48Q7A6ONOFAZINLIMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719047 | CS-1003 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 42T48Q7A6O | NOFAZINLIMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.